# Early Versus Late Ofatumumab (Kesimpta®) Use in Austrian RMS-Patients Over 2 Years

> **NCT05776888** · — · ACTIVE_NOT_RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 106 (actual)

## Conditions studied

- Relapsing Multiple Sclerosis

## Interventions

- **OTHER:** Ofatumumab

## Key facts

- **NCT ID:** NCT05776888
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-07-10
- **Primary completion:** 2026-08-31
- **Final completion:** 2026-08-31
- **Target enrollment:** 106 (ACTUAL)
- **Last updated:** 2025-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05776888

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05776888, "Early Versus Late Ofatumumab (Kesimpta®) Use in Austrian RMS-Patients Over 2 Years". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05776888. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*